Citigroup Reiterates Buy Rating on Kiniksa Pharmaceuticals, Ltd. (KNSA)

Market Context

Kiniksa Pharmaceuticals, Ltd. operates in the Healthcare sector. The stock currently trades at $81.39 with a market capitalization of $3.0B. The stock has gained 201.7% over the past 52 weeks.

Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kiniksa Pharmaceuticals, Ltd..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Kiniksa Pharmaceuticals, Ltd.

Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 29, 2026	Citigroup	Buy	N/A
Jul 23, 2026	Goldman Sachs	Buy	N/A
Jul 13, 2026	Wells Fargo	Overweight	N/A
Jun 29, 2026	Wedbush	Outperform	N/A
Apr 29, 2026	Wells Fargo	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View KNSA Stock Page